Stockscreener 앱 받기
100.90
1.63%
1.61
전일 마감가:
$99.29
열려 있는:
$99.35
하루 거래량:
2.09M
Relative Volume:
4.64
시가총액:
$3.32B
수익:
$2.32B
순이익/손실:
$82.93M
주가수익비율:
40.04
EPS:
2.52
순현금흐름:
$203.54M
1주 성능:
+2.34%
1개월 성능:
+4.57%
6개월 성능:
+9.71%
1년 성능:
+3.19%
1일 변동 폭
$98.95
$100.99
1주일 범위
$98.09
$100.99
52주 변동 폭
$82.15
$100.99
아메디시스 Stock (AMED) Company Profile
명칭
Amedisys Inc
전화
(225) 292-2031
주소
3854 AMERICAN WAY, BATON ROUGE, LA
AMED을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AMED
Amedisys Inc
|
100.90 | 3.27B | 2.32B | 82.93M | 203.54M | 2.52 |
|
HCA
Hca Healthcare Inc
|
370.94 | 85.13B | 72.70B | 5.97B | 7.29B | 23.79 |
|
THC
Tenet Healthcare Corp
|
162.14 | 14.16B | 20.52B | 1.46B | 1.41B | 15.12 |
|
FMS
Fresenius Medical Care Ag Adr
|
23.77 | 14.33B | 20.92B | 666.06M | 1.85B | 1.1422 |
|
EHC
Encompass Health Corp
|
116.21 | 11.48B | 5.51B | 494.70M | 386.40M | 4.84 |
|
DVA
Davita Inc
|
128.62 | 10.62B | 12.82B | 936.34M | 1.47B | 10.74 |
아메디시스 Stock (AMED) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-07-29 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2024-07-01 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-06-07 | 다운그레이드 | Truist | Buy → Hold |
| 2023-04-21 | 개시 | Cantor Fitzgerald | Neutral |
| 2023-03-13 | 개시 | Barclays | Equal Weight |
| 2022-10-27 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2022-08-02 | 다운그레이드 | UBS | Neutral → Sell |
| 2022-06-29 | 개시 | Stifel | Hold |
| 2022-06-21 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-03-01 | 업그레이드 | UBS | Sell → Neutral |
| 2022-02-25 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2022-02-25 | 재확인 | Credit Suisse | Outperform |
| 2022-02-25 | 재확인 | Oppenheimer | Outperform |
| 2022-02-25 | 재확인 | RBC Capital Mkts | Outperform |
| 2022-02-25 | 재확인 | Raymond James | Outperform |
| 2022-02-25 | 재확인 | Truist | Buy |
| 2021-09-27 | 개시 | SVB Leerink | Mkt Perform |
| 2021-09-24 | 개시 | UBS | Sell |
| 2021-09-10 | 개시 | Cowen | Market Perform |
| 2021-08-10 | 재확인 | The Benchmark Company | Buy |
| 2021-08-05 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2020-08-20 | 재개 | Barclays | Overweight |
| 2020-07-30 | 재확인 | The Benchmark Company | Buy |
| 2020-06-18 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2020-05-07 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2020-03-09 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2020-01-17 | 개시 | Credit Suisse | Outperform |
| 2019-11-01 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2019-10-22 | 재개 | Stephens | Equal-Weight |
| 2019-09-17 | 개시 | Deutsche Bank | Buy |
| 2019-05-02 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2018-12-14 | 개시 | Barclays | Equal Weight |
| 2018-11-16 | 개시 | UBS | Neutral |
| 2018-10-30 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2018-07-03 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2018-03-19 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2017-11-09 | 재확인 | RBC Capital Mkts | Sector Perform |
| 2017-11-09 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2017-11-08 | 재확인 | Mizuho | Buy |
| 2017-11-02 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2017-08-21 | 개시 | BofA/Merrill | Neutral |
모두보기
아메디시스 주식(AMED)의 최신 뉴스
Amedisys and UnitedHealth Resolve Merger Opposition - TipRanks
Amedisys (AMED) Settles with DOJ Over $3.3 Billion UnitedHealth Deal - GuruFocus
UnitedHealth and Amedisys reach settlement with DOJ over $3.3B merger - Healthcare Dive
US Justice Dept. says broad divestitures required to resolve challenge to Unitedhealth’s acquisition of Amedisys - Reuters
AMED & UNH reach DOJ settlement; merger path clears despite divestitures | AMED SEC FilingForm 8-K - Stock Titan
Amedisys gains on settlement with DOJ over sale to UnitedHealth (AMED:NASDAQ) - Seeking Alpha
Amedisys, Inc. Reports Strong Q2 2025 Revenue Growth - TipRanks
Returns On Capital At Amedisys (NASDAQ:AMED) Have Hit The Brakes - 富途牛牛
Amedisys: Thoughts On UnitedHealth Merger, Plus Underlying Factors - Seeking Alpha
How does Amedisys Inc. generate profit in a changing economyMassive profits - Jammu Links News
How strong is Amedisys Inc. company’s balance sheetExplosive portfolio gains - Jammu Links News
What institutional investors are buying Amedisys Inc. stockAchieve superior returns through strategic trading - Jammu Links News
What are analysts’ price targets for Amedisys Inc. in the next 12 monthsAchieve consistent returns with proven methods - Jammu Links News
How volatile is Amedisys Inc. stock compared to the marketHigh-performance investment picks - Jammu Links News
How does Amedisys Inc. compare to its industry peersExponentially increasing returns - Jammu Links News
What catalysts could drive Amedisys Inc. stock higher in 2025Rapid growth opportunities - Jammu Links News
Should I hold or sell Amedisys Inc. stock in 2025Unlock exclusive stock market forecasts - Jammu Links News
What is the dividend policy of Amedisys Inc. stockStay ahead with advanced stock screening tools - Jammu Links News
What makes Amedisys Inc. stock price move sharplyInvest smarter with daily stock recommendations - Jammu Links News
Why is Amedisys Inc. stock attracting strong analyst attentionMaximize returns with disciplined trading approaches - Jammu Links News
What are the latest earnings results for Amedisys Inc.Rapid portfolio appreciation - Jammu Links News
When is Amedisys Inc. stock expected to show significant growthAchieve rapid portfolio growth with expert help - Jammu Links News
What markets is ELWS expanding into Is Amedisys Inc. stock a good long term investment optionUnlock daily market insights for better decisions - Jammu Links News
Amedisys (AMED) is a Top-Ranked Value Stock: Should You Buy? - Yahoo Finance
Real time pattern detection on Amedisys Inc. stockFast Exit and Entry Strategy Guide Offered - metal.it
Amedisys Exceeds Q2 Revenue Expectations with Strong Financial Profile - AInvest
Amedisys Receives Hold Rating from William Blair; Analyst Consensus Remains Hold - AInvest
Amedisys (AMED) Q2 Revenue Tops 5% - The Globe and Mail
Amedisys (AMED) Q2 Revenue Tops 5% - The Motley Fool
Amedisys Reports Q2 2025 Financial Results Amid Merger - The Globe and Mail
As Mediation Nears, Amedisys Delivers Strong Q2, Charts Impact From Proposed CMS Payment Cut - Home Health Care News
Amedisys stock hits 52-week high at 98.63 USD - Investing.com Australia
Amedisys stock hits 52-week high at 98.63 USD By Investing.com - Investing.com South Africa
How Investors Are Reacting To Amedisys (AMED) Rebound in Year-to-Date Earnings Amid Quarterly Decline - simplywall.st
Amedisys Sees Hospice Revenue Rise Amid DOJ’s UnitedHealth Group Acquisition Lawsuit - Hospice News
AMEDISYS INC SEC 10-Q Report - TradingView
Amedisys Inc. Volume Confirms Breakout — Analysts BullishAI Forecast for Trending Stocks Indicates Upside - beatles.ru
Amedisys 2025 Q2 Earnings Record High Net Income Despite Decline - AInvest
Amedisys: Q2 Earnings Snapshot - Huron Daily Tribune
Amedisys (AMED) Q2 2025 Earnings: Resilience Amid Merger Costs and Industry Consolidation - AInvest
Amedisys (AMED) Q2 Earnings Beat: A Strategic Buy Opportunity Amid Merger Uncertainty? - AInvest
Here's What Key Metrics Tell Us About Amedisys (AMED) Q2 Earnings - Nasdaq
Amedisys (AMED) Beats Q2 Earnings and Revenue Estimates - Yahoo Finance
Amedisys Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Amedisys earnings beat by $0.18, revenue topped estimates - Investing.com Canada
Amedisys Outpaces Expectations With Strong Q2 Results - Finimize
아메디시스 (AMED) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.11%
0.37%
자본화:
|
볼륨(24시간):